The science of the new statement is solid. In 2002, the USPSTF recommended screening for osteoporosis in all women age 65 and older, and in women age 60-64 with "risk factors," but declined to specify which precise risk factors to use, and said nothing about screening in younger women or men. The new guideline advises using the FRAX risk assessment tool to determine if a younger woman has a fracture risk level that would make her likely to benefit from screening, and cautions that there isn't yet enough evidence to recommend screening in men. So far, so good. So what's the problem, and where in the process did politics get involved?
The problem, in my view, is that all of these facts were known more than two years ago, in November 2008, when a previous incarnation of the USPSTF (of which about half of the members remain on the panel) actually voted for these new recommendations. At that time, a typical interval between a Task Force vote to recommendation release was 9 to 12 months, and even that length of time was considered by many USPSTF members to be unacceptable, given the critical public health implications of many of these statements. (In a congressional hearing held in December 2009, USPSTF Chair Ned Calonge acknowledged that the 16-month interval between the vote and publication of the breast cancer screening recommendations was "much too long.")
After the mammography debacle, though, the output of the USPSTF ground to a halt. After releasing an average of one new or updated recommendation each month for the previous 3 years, the Task Force published no new recommendations for nearly a year. All in-progress statements, including several (such as screening for osteoporosis) that were in press as of December 2009, were ordered to be withdrawn by a White House and DHHS leadership that would tolerate no further potential threats to the passage of health reform legislation. And even after the Affordable Care Act became law in March 2010, no remotely controversial statements were permitted to be introduced into the USPSTF's new public comment process until after the November 2010 midterm elections. Statements that were shelved for a year or more (and remain unreleased, even in draft form) include clinically significant, but politically sensitive topics such as breast cancer chemoprevention (voted in March 2009), screening for oral cancer (voted in March 2009), and vitamin D supplementation (voted in November 2009).
If you've read this blog before, you know that I support health reform, even though I don't agree with many specific components of the legislation. And I understand the argument that not presenting health reform opponents with a convenient target might be a reasonable short-term, or even long-term, political strategy. But to a family physician, "health reform" is more than a nice idea, a weighty piece of legislation, or a partisan political achievement. It's about doing what's best for our patients. And if we achieve "health reform" that grants insurance cards to 32 million more people, but doesn't provide them with reliable access to primary care; selectively muzzles experts whom primary care physicians trust to tell them what works and what doesn't in clinical prevention; and willfully allows outdated recommendations to guide coverage of primary care screening to prevent many of 1.5 million life-altering osteoporotic fractures that occur in the U.S. each year, then, well, we have achieved very little at all.
